Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

26.26 -0.17 (-0.64%)

Delayed Quote Updated: 3:17 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Zai Lab Q3 Earnings Call Highlights ↗

November 06, 2026

Zai Lab (NASDAQ:ZLAB) reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate...

Via MarketBeat

Topics Earnings

Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Zai Lab's China business stabilizes as its lead cancer drug nears a 2027 filing.

Via The Motley Fool

Topics Earnings

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study ↗

October 23, 2026

Zai Lab (NASDAQ:ZLAB) presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with or...

Via MarketBeat

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗

September 03, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Zoci advances toward global registrational trials as net product revenue rises 11%.

Via The Motley Fool

Topics Earnings

Zai Lab Q2 Earnings Call Highlights ↗

August 07, 2026

Zai Lab (NASDAQ:ZLAB) said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a...

Via MarketBeat

Topics Earnings

Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗

June 01, 2026

Zai Lab (ZLAB) Q1 2026 Earnings Transcript

Via The Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

Via The Motley Fool

Topics Economy Regulatory Compliance

Zai Lab Q1 Earnings Call Highlights ↗

May 09, 2026

Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology...

Via MarketBeat

Topics Earnings

Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance

November 19, 2025

Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025...

Via MarketMinute

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback ↗

September 11, 2025

Via Benzinga

Topics Earnings

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects ↗

June 30, 2025

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.

Via Benzinga

ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria ↗

June 16, 2025

ZAI LAB LTD-ADR (NASDAQ:ZLAB) is a high-growth biotech stock meeting Minervini’s Trend Template with strong revenue growth, technical strength, and sector leadership.

Via Chartmill

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday ↗

June 04, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

June 04, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial ↗

June 02, 2025

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.

Via Benzinga

Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio? ↗

April 20, 2025

Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion...

Via Benzinga

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗

April 11, 2025

Via Benzinga

Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria ↗

April 03, 2025

A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB).

Via Chartmill

No Fear And No Panic After A 10% Correction = No Bottom ↗

March 28, 2025

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

Via Talk Markets

Topics Stocks / Equities

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗

March 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.